INNOTEST® sTREM2

INNOTEST sTREM2 is a solid-phase enzyme immunoassay for the quantitative determination of soluble Triggering Receptor Expressed on Myeloid cells 2 (sTREM2) in human cerebrospinal fluid (CSF).

Contact sales for information
For research use only
INNOTEST sTREM2

Product number 81056

96 Tests
INNOTEST sTREM2 CAL-RVC pack

Product number 81057

Please contact your local Fujirebio representative for the availability of this product in your country.

Click here to navigate

  • Contact sales for information
  • Details
  • Conditions of sale
  • Documentation
  • Insights
  • FAQ
  • Product inquiry
  • Related products
  • Details

    This assay should be used in combination with the sTREM2 CAL-RVC pack, article no. 81057 (RUO), of the corresponding lot.
     

    Test principle

    The INNOTEST sTREM2 is a solid-phase enzyme immunoassay in which the sTREM2 protein is captured by a first monoclonal antibody, ADx601 (B02; rabbit; IgG). CSF samples are added and incubated with a biotinylated antibody, ADx602 (C10; rabbit; IgG). Both ADx601 and ADx602 are directed against the ectodomain of human TREM2 and the epitope of ADx601 is further specified in Figure 1. This antigen-antibody complex is then detected by a peroxidase-labeled streptavidin. After addition of substrate working solution, samples will develop a color. The color intensity is a measure for the amount of human sTREM2 protein in the sample.

    INNOTEST sTREM2 test principle

    Figure 1: Test principle INNOTEST sTREM2 (SV = streptavidin; HRP = horseradish peroxidase).

     
    Background

    TREM2 is a transmembrane receptor that is predominantly expressed by microglia in the central nervous system. sTREM2 results from the processing of the TREM2 ectodomain and can be detected in CSF. Studies demonstrated that CSF sTREM2 is a bioactive molecule capable of binding ligands (like Aβ), activating microglia and regulating immune responses during the Alzheimer’s disease (AD) continuum1. CSF sTREM2 seems to be especially increased in early symptomatic stages of late-onset AD, whereas decreased CSF sTREM2 concentrations have been observed at the earliest asymptomatic phase when only abnormal Aβ pathology, but no tau pathology or neurodegeneration, is present. Rare variants in the TREM2 gene increase the risk for late-onset AD, and CSF sTREM2 concentrations have been found to differ between variants2. Altogether, CSF sTREM2 can be seen as a surrogate measure of TREM2-mediated microglia function.

      
    References

    1. Yang J, et al. TREM2 ectodomain and its soluble form in Alzheimer’s disease. J Neuroinflammation, 2020;17:204.
    2. Suárez-Calvet M, et al. Early increase of CSF sTREM2 in Alzheimer’s disease is associated with tau related-neurodegeneration but not with amyloid-β pathology. Mol Neurodegener, 2019;14:1.
  • Conditions of sale

    To read the end user conditions of sale for this product please visit our Resource center.

  • Insights

  • FAQ

  • Product inquiry

    The provision of your data implies your consent to the processing of your data in our database and, depending on the option you choose, to receiving our monthly newsletter by e-mail.

    For more information on how we process your personal data and regarding the rights you have in this respect, we refer to our privacy policy, which we hold at your disposal HERE.

    If you no longer wish to receive our newsletter, you have the option to unsubscribe via the ‘unsubscribe’ tool at the bottom of the newsletter. If you want to have your data removed from our database, please contact us at: privacy@fujirebio.com.